Opus Genetics (NASDAQ:IRD) versus Verastem (NASDAQ:VSTM) Critical Comparison

Opus Genetics (NASDAQ:IRD) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Opus Genetics and Verastem, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	2	0	12	1	2.80
Verastem	1	1	7	2	2.91

Opus Genetics currently has a consensus target price of $10.18, suggesting a potential upside of 142.42%. Verastem has a consensus target price of $15.60, suggesting a potential upside of 263.64%. Given Verastem’s stronger consensus rating and higher possible upside, analysts plainly believe Verastem is more favorable than Opus Genetics.

Insider and Institutional Ownership

15.0% of Opus Genetics shares are owned by institutional investors. Comparatively, 88.4% of Verastem shares are owned by institutional investors. 11.7% of Opus Genetics shares are owned by company insiders. Comparatively, 1.9% of Verastem shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Opus Genetics has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500.

Profitability

This table compares Opus Genetics and Verastem’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-892.36%	-338.88%	-191.21%
Verastem	-391.17%	-486.40%	-91.56%

Valuation & Earnings

This table compares Opus Genetics and Verastem”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Opus Genetics	$14.20 million	24.08	-$49.59 million	($1.33)	-3.16
Verastem	$30.91 million	12.20	-$209.47 million	($2.70)	-1.59

Opus Genetics has higher earnings, but lower revenue than Verastem. Opus Genetics is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.

Summary

Verastem beats Opus Genetics on 8 of the 15 factors compared between the two stocks.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.

About Verastem

Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors. The company is involved in clinical studies, including RAMP 301, a randomized global confirmatory trial to evaluate the combination of Avutometinib and Defactinib for the treatment of patients with recurrent low-grade serous ovarian cancer; RAMP 201, an adaptive two-part multicenter, parallel cohort, randomized open label trial to evaluate the efficacy and safety of Avutometinib and in combination with Defactinib; and FRAME, an investigation of Avutometinib and Defactinib in patients with KRAS mutant cancers and subsequent analyses; and RAMP 204 and 205. It has license agreements with Chugai Pharmaceutical Co., Ltd. for the development, commercialization, and manufacture of products containing Avutometinib; and Pfizer Inc. to research, develop, manufacture, and commercialize products containing Pfizer's inhibitors of FAK for therapeutic, diagnostic, and prophylactic uses in humans. In addition, it has a clinical collaboration agreement with Amgen, Inc. to evaluate the combination of Avutometinib with Amgen's KRAS-G12C inhibitor LUMAKRAS which in Phase 1/2 trial entitled RAMP 203; and a discovery and development collaboration with GenFleet Therapeutics to advance new programs targeting RAS pathway-driven cancers. Verastem, Inc. was incorporated in 2010 and is headquartered in Needham, Massachusetts.